✦ LIBER ✦

A 6 increases time to clinical disease progression in ovarian cancer

Book ID: 120842695
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2008
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200816640-00011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Time-to-progression in breast cancer: A

Time-to-progression in breast cancer: A stratification model for clinical trials

✍ Juan de la Haba-Rodríguez; Enrique Aranda; Antonio Llombart; Ana Lluch; Emilio A 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 160 KB

Pre-clinical assessment of autologous DC

Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease

✍ Nicola Hardwick, Jonathan A. Ledermann, Egla Aitkens, Benny Chain 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 502 KB

Clinical states in prostate cancer: towa

Clinical states in prostate cancer: toward a dynamic model of disease progression

✍ Howard I. Scher; Glenn Heller 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 370 KB

Time from completion of chemotherapy to

Time from completion of chemotherapy to disease progression as a clinically relevant endpoint in women with epithelial ovarian, primary peritoneal, and fallopian tube cancers treated with and without bevacizumab

✍ Randall, L.; Burger, R.; Nguyen, H.; Kong, G.; Bookman, M.; Fleming, G.; Monk, B 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 181 KB

CA15-3: Its relationship to clinical sta

CA15-3: Its relationship to clinical stage and progression to metastatic disease in breast cancer

✍ M. J. Kerin; O. J. McAnena; V. P. O'Malley; H. Grimes; Professor H. F. Given 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB

Abstract There is increasing interest in the potential role of monoclonal antibodies as tumour markers in the early detection of metastatic disease. CA15-3 is a circulating antigen which is relatively specific for breast tissue and defined by two monoclonal antibodies. It is elevated in the serum of

The relevant distinction between “progre

The relevant distinction between “progression” in ovarian cancer drug trials and the clinical decision to change therapy

✍ Maurie Markman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB